argenx (ARGX) Stock Forecast & Price Target

Argenx has demonstrated robust financial growth with revenue for Vyvgart reaching $790 million in Q1 and $949 million in Q2 of 2025, reflecting year-over-year increases of 98% and 97%, respectively. The company's innovative pre-filled syringe format has significantly expanded its prescriber base, with approximately 1,000 prescribers reported in Q2, including 150 new to Vyvgart, thus enhancing the growth potential. Continued adoption in earlier lines of therapy for generalized myasthenia gravis and the recent expansion into chronic inflammatory demyelinating polyneuropathy underpin a positive trajectory for the company’s revenue and future prospects.

Argenx's outlook appears negative due to the inherent risks associated with clinical trials, where the company's lead assets and future drug candidates may not secure approval or fail to demonstrate significant efficacy, ultimately affecting investor confidence and share value. Additionally, the company's projected market penetration for Vyvgart in Chronic Inflammatory Demyelinating Polyneuropathy remains modest, with only an estimated 24% uptake by 2025 among a targeted patient demographic, which could limit revenue growth. Furthermore, the biopharmaceutical landscape for autoimmune and oncologic diseases is becoming increasingly competitive, with multiple players poised to challenge Argenx's market position and potentially dilute its forecasted profitability.